SAN DIEGO–(BUSINESS WIRE)–Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the addition of three key new members to its leadership team. Aaron Mishel has joined the company as Chief Financial Officer, David Houck as Vice President of CMC (Chemistry, Manufacturing & Controls), and Greg Balani as Director of Business Development. “We are pleased t
Click here to view original post
Copyright © 2023 Biotech Networks, LLC
